Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Day One pens $285M deal for Mersana
Mersana Therapeutics' decision earlier this year to go all-in on its ADC Emi-Le appears to have paid off.
James Waldron
Nov 13, 2025 10:15am
Merck bags $700M from Blackstone, spends $150M to regain asset
Nov 4, 2025 9:15am
Neok exits stealth with $75M to take bispecific ADCs into clinic
Nov 4, 2025 7:00am
GSK pens $357M pact with French biotech for prostate cancer ADC
Oct 27, 2025 4:07am
Takeda strikes Innovent pact worth up to $11.4B
Oct 22, 2025 9:15am
ESMO: The ADC 'rollercoaster' rides on with next-gen meds
Oct 21, 2025 3:00am
